carbon C 14 lerociclib

{
  "id": "MLC-T-ONC-012278",
  "term": "carbon C 14 lerociclib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable radioconjugate composed of lerociclib, an orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of lerociclib. Upon administration, carbon C 14 lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. Labeling of lerociclib with the radioactive tracer carbon C 14 allows for the evaluation of lerociclib's pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).",
  "synonyms": [
    "14C-lerociclib",
    "14C-GB491",
    "[14C]GB491"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/carbon-c-14-lerociclib/"
}